Merck Submits Final Data For Application To Market HPV Vaccine Gardasil To Older Women

Merck on Wednesday announced that it has provided FDA with completed trial data on its human papillomavirus vaccine, Gardasil, in support of its application to market the vaccine to women ages 27 through 45, Reuters reports. FDA in 2006 approved Gardasil for girls and women ages nine through 26 to protect against certain strains of HPV that can lead to cervical cancer and genital warts…

Merck's Gardasil Effective At Preventing HPV, Cervical Disease In Older Women, Study Finds

Merck’s human papillomavirus vaccine, Gardasil, was 90% effective in preventing infection with the virus and cervical disease in women ages 24 to 45, according to a study published Monday in the medical journal Lancet,